Showing results (421-430 of 448) with videos related to

Sort By:
Pageof 45
Journal of the American Geriatrics Society|March 23, 2019
Understanding Caregiver Quality of Life in Caregivers of Hospitalized Older Adults With CancerTina Hsu, Nitya Nathwani, Matthew Loscalzo, et al.
Prostate Cancer and Prostatic Diseases|January 21, 2015
Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxelH H Cheng, R Gulati, A Azad, et al.
Cancer Treatment and Research Communications|July 8, 2019
Randomized trial of oral cyclophosphamide versus oral cyclophosphamide with celecoxib for recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancerRohan Gupta, Mihaela Cristea, Paul Frankel, et al.
Nanoscale|September 16, 2017
Mammalian cell defence mechanisms against the cytotoxicity of NaYF4:(Er,Yb,Gd) nanoparticlesB Sikora, P Kowalik, J Mikulski, et al.
The Lancet. Oncology|July 23, 2013
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trialDavid I Quinn, Catherine M Tangen, Maha Hussain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2007
Phase I trial of intraperitoneal gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavityRobert J Morgan, Timothy W Synold, Bixin Xi, et al.
The Journal of Urology|October 4, 2019
The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical DataE David Crawford, Przemyslaw W Twardowski, Raoul S Concepcion, et al.
Cancer|May 8, 2014
A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinomaMaha Hussain, Stephanie Daignault, Neeraj Agarwal, et al.
The Journal of Clinical Investigation|July 15, 2024
Molecular analysis of primary and metastatic sites in patients with renal cell carcinomaShuchi Gulati, Pedro C Barata, Andrew Elliott, et al.
International Journal of Cancer|September 16, 2014
Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trialAmir Goldkorn, Benjamin Ely, Catherine M Tangen, et al.
Pageof 45